BioNexus Gene Lab Corp.
BGLC
$5.42
$0.234.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.26M | 2.14M | 2.52M | 2.63M | 1.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.26M | 2.14M | 2.52M | 2.63M | 1.97M |
| Cost of Revenue | 1.89M | 1.79M | 2.21M | 2.30M | 1.69M |
| Gross Profit | 368.00K | 343.50K | 309.20K | 326.50K | 288.70K |
| SG&A Expenses | 1.06M | 947.50K | -336.50K | 2.13M | 142.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -77.60K | -29.30K | 1.27M | -465.50K | -19.20K |
| Total Operating Expenses | 2.88M | 2.72M | 3.20M | 3.97M | 1.82M |
| Operating Income | -622.40K | -586.90K | -676.20K | -1.34M | 157.00K |
| Income Before Tax | -616.20K | -623.30K | -422.00K | -1.34M | 254.70K |
| Income Tax Expenses | -- | -- | -73.70K | 1.60K | 55.60K |
| Earnings from Continuing Operations | -616.20K | -623.30K | -348.30K | -1.35M | 199.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -616.20K | -623.30K | -348.30K | -1.35M | 199.10K |
| EBIT | -622.40K | -586.90K | -676.20K | -1.34M | 157.00K |
| EBITDA | -594.60K | -560.30K | -646.70K | -1.30M | 177.20K |
| EPS Basic | -0.34 | -0.35 | -0.19 | -0.75 | 0.11 |
| Normalized Basic EPS | -0.20 | -0.19 | -0.16 | -0.47 | 0.08 |
| EPS Diluted | -0.34 | -0.35 | -0.19 | -0.75 | 0.11 |
| Normalized Diluted EPS | -0.20 | -0.19 | -0.16 | -0.47 | 0.08 |
| Average Basic Shares Outstanding | 1.80M | 1.80M | 1.80M | 1.80M | 1.77M |
| Average Diluted Shares Outstanding | 1.80M | 1.80M | 1.80M | 1.80M | 1.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |